These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34703545)

  • 1. Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties.
    Hempel T; Elez K; Krüger N; Raich L; Shrimp JH; Danov O; Jonigk D; Braun A; Shen M; Hall MD; Pöhlmann S; Hoffmann M; Noé F
    Chem Sci; 2021 Oct; 12(38):12600-12609. PubMed ID: 34703545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
    Li K; Meyerholz DK; Bartlett JA; McCray PB
    mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semi-Mechanistic Pharmacokinetic-Pharmacodynamic Model of Camostat Mesylate-Predicted Efficacy against SARS-CoV-2 in COVID-19.
    Kosinsky Y; Peskov K; Stanski DR; Wetmore D; Vinetz J
    Microbiol Spectr; 2022 Apr; 10(2):e0216721. PubMed ID: 35412356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
    Hoffmann M; Hofmann-Winkler H; Smith JC; Krüger N; Arora P; Sørensen LK; Søgaard OS; Hasselstrøm JB; Winkler M; Hempel T; Raich L; Olsson S; Danov O; Jonigk D; Yamazoe T; Yamatsuta K; Mizuno H; Ludwig S; Noé F; Kjolby M; Braun A; Sheltzer JM; Pöhlmann S
    EBioMedicine; 2021 Mar; 65():103255. PubMed ID: 33676899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
    Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
    J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
    Zhu H; Du W; Song M; Liu Q; Herrmann A; Huang Q
    Comput Struct Biotechnol J; 2021; 19():467-476. PubMed ID: 33505639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Silico Analysis and Synthesis of Nafamostat Derivatives and Evaluation of Their Anti-SARS-CoV-2 Activity.
    Fujimoto KJ; Hobbs DCF; Umeda M; Nagata A; Yamaguchi R; Sato Y; Sato A; Ohmatsu K; Ooi T; Yanai T; Kimura H; Murata T
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism of inhibiting the SARS-CoV-2 cell entry facilitator TMPRSS2 with camostat and nafamostat.
    Hempel T; Raich L; Olsson S; Azouz NP; Klingler AM; Hoffmann M; Pöhlmann S; Rothenberg ME; Noé F
    Chem Sci; 2021 Jan; 12(3):983-992. PubMed ID: 35382133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
    Sonawane KD; Barale SS; Dhanavade MJ; Waghmare SR; Nadaf NH; Kamble SA; Mohammed AA; Makandar AM; Fandilolu PM; Dound AS; Naik NM; More VB
    Inform Med Unlocked; 2021; 24():100597. PubMed ID: 34075338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2.
    Wagoner J; Herring S; Hsiang TY; Ianevski A; Biering SB; Xu S; Hoffmann M; Pöhlmann S; Gale M; Aittokallio T; Schiffer JT; White JM; Polyak SJ
    Microbiol Spectr; 2022 Oct; 10(5):e0333122. PubMed ID: 36190406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic block of SARS-CoV-2 infection by combined drug inhibition of the host entry factors PIKfyve kinase and TMPRSS2 protease.
    Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
    bioRxiv; 2021 Aug; ():. PubMed ID: 34100014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate.
    Hernández-Mitre MP; Morpeth SC; Venkatesh B; Hills TE; Davis J; Mahar RK; McPhee G; Jones M; Totterdell J; Tong SYC; Roberts JA
    Clin Microbiol Infect; 2024 Jun; 30(6):743-754. PubMed ID: 38331253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
    Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
    bioRxiv; 2020 Aug; ():. PubMed ID: 32596694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
    Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K
    Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19.
    Shrimp JH; Kales SC; Sanderson PE; Simeonov A; Shen M; Hall MD
    ACS Pharmacol Transl Sci; 2020 Oct; 3(5):997-1007. PubMed ID: 33062952
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Salleh MZ; Deris ZZ
    Life (Basel); 2022 Feb; 12(2):. PubMed ID: 35207518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
    Kondo A; Fujimoto KJ; Yanai T
    Phys Chem Chem Phys; 2023 Aug; 25(30):20597-20605. PubMed ID: 37477571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
    Mahoney M; Damalanka VC; Tartell MA; Chung DH; Lourenço AL; Pwee D; Mayer Bridwell AE; Hoffmann M; Voss J; Karmakar P; Azouz NP; Klingler AM; Rothlauf PW; Thompson CE; Lee M; Klampfer L; Stallings CL; Rothenberg ME; Pöhlmann S; Whelan SPJ; O'Donoghue AJ; Craik CS; Janetka JW
    Proc Natl Acad Sci U S A; 2021 Oct; 118(43):. PubMed ID: 34635581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.